PDCD1 and metastatic neoplasm: Therefore, the phase 2 KEYNOTE-158 trial, pembrolizumab, a Programmed Cell Death Protein 1 (PD-1) inhibitor, achieved an objective response of 14.3% in patients who had received one or more prior chemotherapy treatments for recurrent or metastatic disease and had PD-L1–positive tumors [10].